Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. The company's growth is often in the single ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
A new study from an international team of researchers has identified hundreds of new genetic variants linked to increased ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback